Non-Muscle-Invasive Bladder Cancer Treatment Market, Global Outlook and Forecast 2022-2028
This report contains market size and forecasts of Non-Muscle-Invasive Bladder Cancer Treatment in Global, including the following market information:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Muscle-Invasive Bladder Cancer Treatment include Ferring Pharmaceuticals, Merck, Sesen Bio, CG Oncology, ImmunityBio, Theralase and Viventia Bio Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Muscle-Invasive Bladder Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Type, 2021 (%)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Application, 2021 (%)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Muscle-Invasive Bladder Cancer Treatment include Ferring Pharmaceuticals, Merck, Sesen Bio, CG Oncology, ImmunityBio, Theralase and Viventia Bio Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Muscle-Invasive Bladder Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Type, 2021 (%)
- Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
- Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
- High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Clinics
- Others
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Ferring Pharmaceuticals
- Merck
- Sesen Bio
- CG Oncology
- ImmunityBio
- Theralase
- Viventia Bio Inc.
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Non-Muscle-Invasive Bladder Cancer Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL NON-MUSCLE-INVASIVE BLADDER CANCER TREATMENT OVERALL MARKET SIZE
2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2021 VS 2028
2.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.2 Top Global Non-Muscle-Invasive Bladder Cancer Treatment Companies Ranked by Revenue
3.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Muscle-Invasive Bladder Cancer Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Markets, 2021 & 2028
4.1.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.2 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2022
4.2.2 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2023-2028
4.2.3 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2022
5.2.2 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2023-2028
5.2.3 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2021 & 2028
6.2 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2022
6.2.2 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2023-2028
6.2.3 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.3.2 US Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.3.3 Canada Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.3.4 Mexico Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.4.2 Germany Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.3 France Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.4 U.K. Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.5 Italy Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.6 Russia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.8 Benelux Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.5.2 China Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.3 Japan Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.4 South Korea Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.6 India Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.6.2 Brazil Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.6.3 Argentina Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.7.2 Turkey Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7.3 Israel Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7.5 UAE Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Ferring Pharmaceuticals
7.1.1 Ferring Pharmaceuticals Corporate Summary
7.1.2 Ferring Pharmaceuticals Business Overview
7.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.1.4 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.1.5 Ferring Pharmaceuticals Key News
7.2 Merck
7.2.1 Merck Corporate Summary
7.2.2 Merck Business Overview
7.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.2.4 Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.2.5 Merck Key News
7.3 Sesen Bio
7.3.1 Sesen Bio Corporate Summary
7.3.2 Sesen Bio Business Overview
7.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.3.4 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.3.5 Sesen Bio Key News
7.4 CG Oncology
7.4.1 CG Oncology Corporate Summary
7.4.2 CG Oncology Business Overview
7.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.4.4 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.4.5 CG Oncology Key News
7.5 ImmunityBio
7.5.1 ImmunityBio Corporate Summary
7.5.2 ImmunityBio Business Overview
7.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.5.4 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.5.5 ImmunityBio Key News
7.6 Theralase
7.6.1 Theralase Corporate Summary
7.6.2 Theralase Business Overview
7.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.6.4 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.6.5 Theralase Key News
7.7 Viventia Bio Inc.
7.7.1 Viventia Bio Inc. Corporate Summary
7.7.2 Viventia Bio Inc. Business Overview
7.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.7.4 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.7.5 Viventia Bio Inc. Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Non-Muscle-Invasive Bladder Cancer Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL NON-MUSCLE-INVASIVE BLADDER CANCER TREATMENT OVERALL MARKET SIZE
2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2021 VS 2028
2.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.2 Top Global Non-Muscle-Invasive Bladder Cancer Treatment Companies Ranked by Revenue
3.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Muscle-Invasive Bladder Cancer Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Markets, 2021 & 2028
4.1.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.2 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2022
4.2.2 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2023-2028
4.2.3 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2022
5.2.2 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2023-2028
5.2.3 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2021 & 2028
6.2 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2022
6.2.2 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2023-2028
6.2.3 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.3.2 US Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.3.3 Canada Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.3.4 Mexico Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.4.2 Germany Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.3 France Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.4 U.K. Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.5 Italy Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.6 Russia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.4.8 Benelux Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.5.2 China Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.3 Japan Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.4 South Korea Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.5.6 India Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.6.2 Brazil Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.6.3 Argentina Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028
6.7.2 Turkey Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7.3 Israel Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
6.7.5 UAE Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Ferring Pharmaceuticals
7.1.1 Ferring Pharmaceuticals Corporate Summary
7.1.2 Ferring Pharmaceuticals Business Overview
7.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.1.4 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.1.5 Ferring Pharmaceuticals Key News
7.2 Merck
7.2.1 Merck Corporate Summary
7.2.2 Merck Business Overview
7.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.2.4 Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.2.5 Merck Key News
7.3 Sesen Bio
7.3.1 Sesen Bio Corporate Summary
7.3.2 Sesen Bio Business Overview
7.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.3.4 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.3.5 Sesen Bio Key News
7.4 CG Oncology
7.4.1 CG Oncology Corporate Summary
7.4.2 CG Oncology Business Overview
7.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.4.4 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.4.5 CG Oncology Key News
7.5 ImmunityBio
7.5.1 ImmunityBio Corporate Summary
7.5.2 ImmunityBio Business Overview
7.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.5.4 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.5.5 ImmunityBio Key News
7.6 Theralase
7.6.1 Theralase Corporate Summary
7.6.2 Theralase Business Overview
7.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.6.4 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.6.5 Theralase Key News
7.7 Viventia Bio Inc.
7.7.1 Viventia Bio Inc. Corporate Summary
7.7.2 Viventia Bio Inc. Business Overview
7.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.7.4 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2017-2022)
7.7.5 Viventia Bio Inc. Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Non-Muscle-Invasive Bladder Cancer Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers in Global Market
Table 3. Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Muscle-Invasive Bladder Cancer Treatment in Global Market
Table 5. Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
Table 9. List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Ferring Pharmaceuticals Corporate Summary
Table 31. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 32. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Merck Corporate Summary
Table 34. Merck Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 35. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Sesen Bio Corporate Summary
Table 37. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 38. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 39. CG Oncology Corporate Summary
Table 40. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 41. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 42. ImmunityBio Corporate Summary
Table 43. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 44. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Theralase Corporate Summary
Table 46. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 47. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Viventia Bio Inc. Corporate Summary
Table 49. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 50. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 1. Non-Muscle-Invasive Bladder Cancer Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers in Global Market
Table 3. Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Muscle-Invasive Bladder Cancer Treatment in Global Market
Table 5. Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
Table 9. List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Ferring Pharmaceuticals Corporate Summary
Table 31. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 32. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Merck Corporate Summary
Table 34. Merck Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 35. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Sesen Bio Corporate Summary
Table 37. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 38. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 39. CG Oncology Corporate Summary
Table 40. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 41. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 42. ImmunityBio Corporate Summary
Table 43. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 44. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Theralase Corporate Summary
Table 46. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 47. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Viventia Bio Inc. Corporate Summary
Table 49. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 50. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Type in 2021
Figure 2. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Application in 2021
Figure 3. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2021
Figure 8. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 12. US Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 24. China Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Type in 2021
Figure 2. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Application in 2021
Figure 3. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2021
Figure 8. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 12. US Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 24. China Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
